HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

HUTCHMED (China) LimitedNASDAQ: HCM

Investing Cash Flow · Q2 FY2025 · quarter ended Jun 2025

Investing cash flow turns positive

Q2 FY2025 investing cash flow was $8.8M, compared with -$2.72M a year earlier. Trailing-twelve-month investing cash flow was -$73.03M.

Context

  • Investing cash flow amounted to 5.4% of revenue in FY2025, down 9.9 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly investing cash flow holds near $8.8M or moves back toward the trailing-twelve-month quarterly average of -$18.26M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2025
$8.8M+0.0% QoQ
Last fiscal yearDec 2025
-$29.49M-69.3% YoY
LTMJun 2025
-$73.03M-476.7% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+423.7%——
1 year-69.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(29.49M) USD
Year-over-year change
+69.3%

Investing Cash Flow vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -476.7% is the lowest of 9, against a peer median of +217.4%.
  • Investing cash flow amounts to 12.1% of revenue for HCM, versus a peer median of 43.7%.
HCM Competitors
Investing Cash Flow for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$5.64B USD—+26.9%136.5%
BNTXBioNTech SELTM Jun 2026€1.03B EUR-158.3%+306.5%39.1%
AAPGAscentage Pharma Group InternationalFY2025CN¥1B CNY+176.2%+37.5%179.1%
LEGNLegend Biotech CorporationLTM Sep 2026$226.82M USD+1455.9%—16.7%
INCYIncyte CorporationLTM Jun 2026$224.83M USD+23174.4%+9.3%3.9%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$109.11M USD+258.7%—48.4%
EXELExelixis, Inc.LTM Jul 2026$93.01M USD+840.9%—3.8%
HCMHUTCHMED (China) LimitedLTM Jun 2025$73.03M USD-476.7%—12.1%
RCUSArcus Biosciences, Inc.LTM Jun 2026$63M USD-67.0%—53.8%
ZLABZai Lab LimitedLTM Jun 2026$39.05M USD-28.3%-9.8%8.7%
ANLAdlai Nortye Ltd.LTM Jun 2024$4.81M USD——74.1%
Peer median (excluding HCM) —+217.4%+26.9%43.7%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.04M)(360.39M)100.78M37.73M458.12M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
Deferred Income Tax(115.14M)0(102.76M)00
Stock-Based Compensation41.99M30.59M36.6M21.61M15.29M
Change in Working Capital32.46M58.7M71.15M(62.17M)(61.02M)
Accounts Receivables(35.63M)(14.45M)(21.34M)(41.57M)28.94M
Inventory(16M)(21.21M)4.14M(772K)9.57M
Accounts Payables9.57M29.94M(32.54M)03.02M
Other Working Capital74.53M64.04M120.89M(19.82M)(102.55M)
Other Non-Cash Items(3.68M)(6.17M)105.28M(9.01M)(490.56M)
Operating Cash Flow(204.22M)(268.6M)219.26M497K(64.83M)
Capital Expenditures(16.76M)(36.66M)(32.61M)(17.93M)(14.19M)
Acquisitions (Net)159.12M324K(2.99M)028.07K
Purchases of Investments(1.37B)(1.2B)(1.63B)(1.85B)(2.75B)
Sales of Investments921.36M1.52B1.37B1.77B2.74B
Other Investing Activities930K16.49M29.5M1.28M0
Investing Cash Flow(306.32M)296.59M(291.14M)(96.06M)(29.49M)
Debt Repayment(579.77K)(9.17M)61.71M5.61M6.27M
Common Stock Issued717.32M174K5.09M790K1.58M
Common Stock Repurchased(27.31M)(48.08M)(9.07M)(36.06M)0
Dividends Paid(99.74M)(87.44M)000
Other Financing Activities60.34M61.75M(9.07M)(1M)0
Financing Cash Flow650.03M(82.76M)48.66M(30.67M)7.86M
Effect of Forex Changes2.43M(9.49M)(6.47M)(3.4M)3.83M
Net Change in Cash141.91M(64.26M)(29.69M)(129.63M)(82.63M)
Free Cash Flow(220.98M)(305.26M)186.65M(17.44M)(79.01M)

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.